The Growing Glaucoma Drug Landscape: Ophthalmology Times

(MedPage Today) -- Also, should we test new policies like we test new drugs?
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news

Related Links:

The Hydrus microstent used in conjunction with cataract surgery achieves significant and sustained lowering of intraocular pressure in patients with primary open-angle glaucoma.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
Authors: Kish T Abstract Poor patient adherence is fueling keen interest in the development of drugs for glaucoma management. Several long-acting formulations of existing medications are in the early stages of development, as are new therapeutic classes such as guanylate cyclase activators. PMID: 30100690 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
More insight into the eye as a'window into the brain'comes from a study linking glaucoma, age-related macular degeneration, and diabetic retinopathy to a higher risk for Alzheimer's disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Authors: Lee CS, Larson EB, Gibbons LE, Lee AY, McCurry SM, Bowen JD, McCormick WC, Crane PK Abstract INTRODUCTION: Identifying ophthalmic diseases associated with increased risk of Alzheimer's disease (AD) may enable better screening and understanding of those at risk of AD. METHODS: Diagnoses of glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR) were based on International Classification of Diseases, 9th revision, codes for 3877 participants from the Adult Changes in Thought study. The adjusted hazard ratio for developing probable or possible AD for recent (within 5 years) an...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
The consensus on the progressive blindness of glaucoma is that the primary cause is rising pressure in the eye, resulting from an age-related failure of fluid flow in surrounding structures. Medications that reduce pressure in the eye, such as by reducing the pace of creation of new fluid, slows down the loss of sight associated with glaucoma, but even after successful treatment the condition can still progresses towards blindness. Researchers may now have identified why this is the case, and here present evidence to suggest that a form of autoimmunity is the process that causes loss of vision. One of the biggest ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Glaucoma is a condition that leads to progressive loss of vision, but its root causes remain unclear. New research says an immune response may be to blame.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Glaucoma affects 300,000 people in the UK and is a leading cause of blindness. Here, Bernie Pedley, 73, from Preston, Lancashire, tells her story of life-changing surgery.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
The competition in the microinvasive glaucoma surgical (MIGS) space is certainly heating up after today’s news. FDA has given a nod to Ivantis’ Hydrus Microstent, which will undoubtedly compete against Glaukos’ iStent. Irvine,CA-based Ivantis’ approval comes on the heels of Glaukos winning a nod from FDA for the iStent inject Trabecular Micro-Bypass System. The Hydrus Microstent is used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The device’s approval is based on the HORIZO...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news
Ivantis said today it won FDA approval for its Hydrus microstent designed to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The Hydrus microstent is designed for minimally invasive microsurgical procedures to reduce eye pressure in patients with glaucoma. The device is multi-modal, the company said, by creating a large opening through the trabecular meshwork and dilating and scaffolding the conventional pathway through which fluid exits the eye. Approval came based on results from the Horizon trial, which the Irvine, Calif.-based company touted as the largest min...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Ivantis Source Type: news
Conditions:   Angle Closure Glaucoma;   Glaucoma;   Cataract Secondary Intervention:   Procedure: phaco- trabeculectomy Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Glaucoma | Opthalmology | Primary Care